Cubist Systematic Strategies LLC boosted its position in Alexion Pharmaceuticals (NASDAQ:ALXN) by 100.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,879 shares of the biopharmaceutical company’s stock after purchasing an additional 2,944 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Alexion Pharmaceuticals were worth $655,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of ALXN. Delpha Capital Management LLC acquired a new position in shares of Alexion Pharmaceuticals during the 4th quarter valued at about $102,000. CNB Bank acquired a new position in shares of Alexion Pharmaceuticals during the 4th quarter valued at about $150,000. Lucia Wealth Services LLC acquired a new position in shares of Alexion Pharmaceuticals during the 1st quarter valued at about $191,000. Financial Gravity Wealth Inc. acquired a new position in shares of Alexion Pharmaceuticals during the 1st quarter valued at about $211,000. Finally, Dupont Capital Management Corp acquired a new position in shares of Alexion Pharmaceuticals during the 1st quarter valued at about $220,000. 92.22% of the stock is owned by institutional investors.
A number of research analysts have recently commented on ALXN shares. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $127.00 price objective for the company in a research note on Thursday, April 19th. Stifel Nicolaus upped their price objective on shares of Alexion Pharmaceuticals from $151.00 to $155.00 and gave the company a “buy” rating in a research note on Friday, April 27th. Nomura upped their price objective on shares of Alexion Pharmaceuticals to $165.00 and gave the company a “buy” rating in a research note on Thursday, April 12th. Credit Suisse Group reaffirmed an “outperform” rating and set a $149.00 price objective (up previously from $147.00) on shares of Alexion Pharmaceuticals in a research note on Friday, March 16th. Finally, BidaskClub downgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, March 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nineteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $160.00.
In other Alexion Pharmaceuticals news, EVP John J. Orloff sold 2,115 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The stock was sold at an average price of $118.53, for a total value of $250,690.95. Following the completion of the transaction, the executive vice president now owns 31,790 shares in the company, valued at approximately $3,768,068.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Christopher J. Coughlin purchased 10,000 shares of the firm’s stock in a transaction on Monday, April 30th. The stock was bought at an average price of $120.79 per share, with a total value of $1,207,900.00. Following the acquisition, the director now owns 26,333 shares in the company, valued at $3,180,763.07. The disclosure for this purchase can be found here. 4.35% of the stock is owned by corporate insiders.
ALXN opened at $122.43 on Wednesday. The company has a market cap of $27.77 billion, a P/E ratio of 23.12, a price-to-earnings-growth ratio of 1.12 and a beta of 1.11. Alexion Pharmaceuticals has a 1 year low of $102.10 and a 1 year high of $149.34. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.35 and a quick ratio of 2.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, April 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.18. The firm had revenue of $930.90 million during the quarter, compared to the consensus estimate of $920.50 million. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The company’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.38 EPS. analysts expect that Alexion Pharmaceuticals will post 6.28 earnings per share for the current year.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.